The prospects of an oral taxane chemotherapy – providing similar efficacy to intravenous (I.V.) with a better toxicity profile – have drawn players to the field that include Odonate Therapeutics Inc. and Athenex Inc., the latter with a phase III trial fully enrolled and the former with a late-stage experiment expected to finish sign-ups in the second half of this year.
As the Philippine Department of Justice (PDOJ) said it found probable cause to indict Sanofi SA and government officials over deaths caused by the Paris-based pharma giant's dengue vaccine, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed the BLA for the product in an uneventful session.
Zafgen Inc. CEO Jeffrey Hatfield said the firm has backup compounds for ZGN-1258 to treat Prader-Willi syndrome (PWS) and "remains committed" to the condition. "We're going to evaluate all of our options to try and unlock potential value we see in methionine aminopeptidase 2 [MetAP2] inhibition for this terrible disease."
Snipr Biome ApS was "flying a little bit under the radar" until the company had "something worth listening to," CEO Christian Grondahl told BioWorld, and the day for talking arrived with the Copenhagen-based company raising $50 million in series A cash.
Cerebral Therapeutics Inc. CEO Dan Abrams told BioWorld that his firm's closing of the $7.8 million extension to its series A financing by Granite Point Capital Management LP and Vivo Capital LLC should "allow us to do a substantial phase II trial" that will bring an epilepsy drug-device combo therapy to the next level.
As the Philippine Department of Justice (PDOJ) said it found probable cause to indict Sanofi SA and government officials over deaths caused by the Paris-based pharma giant's dengue vaccine, the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed the BLA for the product in an uneventful session.
Beam Therapeutics Inc. CEO John Evans told BioWorld that the company's $135 million series B influx – following sooner than some expected the $87 million series A raise last May – is meant to "make sure that resources aren't the limiting factor" in pushing along the company's next-generation CRISPR technologies, expanding the pipeline of base editing programs, and adding to the firm's scientific and technical leadership.